NCT03422536 - Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 5, 2017

Primary Completion Date

March 29, 2022

Study Completion Date

April 5, 2022

Conditions

Head and Neck Basaloid CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaSquamous Cell Carcinoma of Unknown Primary OriginStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IV Nasopharyngeal Keratinizing Squamous Cell CarcinomaStage IV Oropharyngeal Squamous Cell CarcinomaStage IVA Lip and Oral Cavity Squamous Cell CarcinomaStage IVA Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage IVA Nasopharyngeal Keratinizing Squamous Cell CarcinomaStage IVA Oropharyngeal Squamous Cell CarcinomaStage IVB Lip and Oral Cavity Squamous Cell CarcinomaStage IVB Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage IVB Nasopharyngeal Keratinizing Squamous Cell CarcinomaStage IVB Oropharyngeal Squamous Cell CarcinomaStage IVC Lip and Oral Cavity Squamous Cell CarcinomaStage IVC Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage IVC Nasopharyngeal Keratinizing Squamous Cell CarcinomaStage IVC Oropharyngeal Squamous Cell CarcinomaHead and Neck CancerOropharyngeal CancerHNSCCStage IV Lip and Oral Cavity Squamous Cell Carcinoma

Interventions

BIOLOGICAL

Cetuximab

Given IV

DRUG

Ficlatuzumab

Given IV

Trial Locations (6)

19111

Fox Chase Cancer Center, Philadelphia

29425

Medical University of South Carolina, Charleston

30322

Winship Cancer Institute of Emory University, Atlanta

33612

Moffitt Cancer Center, Tampa

85719

The University of Arizona Cancer Center, Tucson

06520

Yale Cancer Center, New Haven

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Arizona

OTHER